RECRUITING

Dendritic Cell Immunotherapy for Treatment of Adult GBM

Conditions

Glioblastoma (GBM)Dendritic Cell Vaccine Immunotherapy Tumor vaccine

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: - Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation

Official Title

Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma

Quick Facts

Study Start:2025-03-17

Study Completion:2032-03

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06805305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age 18 years or older 4. Presumed diagnosis of GBM deemed to be potentially resectable and deemed to be a good candidate for postoperative standard of care temozolomide and radiation therapy. 1. The surgical objective is for gross total resection (GTR)/near-total resection (NTR) defined as greater than or equal to 95% of contrast enhancing (CE) tumor removed plus less than or equal to 1 cm3 residual CE tumor. Patients with subtotal resection will still be eligible if at least 70% of the CE tumor is resected. 2. Eligibility will be confirmed after surgery when diagnosis of GBM IDH-wt confirmed prior to randomization. 3. Patients with prior biopsy or subtotal resection are eligible if no other anti-cancer treatment received for glioblastoma and additional resection indicated. 5. Ability to receive filgrastim (e.g. Neupogen), leukapheresis and 3 bi-weekly injections of DOC1021 near deep cervical lymph nodes + weekly pIFN x 6 weeks. 6. Females of reproductive potential must have a negative serum pregnancy test and agree to use effective contraception (as determined appropriate for the patient by the investigator) during study treatment. 7. Adequate kidney, liver, bone marrow function, and immune function, as follows: 1. Hemoglobin ≥ 8.0 gm/dL (use of transfusion or other intervention to achieve is acceptable) 2. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3 3. Platelet count ≥ 75,000/mm3 4. Calculated creatinine clearance (CrCl) \> 30 mL/min using Cockcroft and Gault formula: 8. Karnofsky Performance Score ≥ 70	1. Multifocal, deep midline, infratentorial, recurrent, leptomeningeal or extracranial disease. 2. Patients who are pregnant or breastfeeding. 3. Known active HIV or hepatitis infection. Patients with HIV that is well-controlled and have undetectable viral titers remain eligible. Patients with history of HCV adequately treated such that RNA viral load is negative also remain eligible. 4. Any severe or uncontrolled medical condition or other condition that could affect participation in this study as determined by the investigator, including but not limited to uncontrolled or severe cardiac disease, systemic autoimmune disorders requiring immunosuppression in the past 2 years, autoimmune hyper/hypothyroidism, untreated vi-ral hepatitis, autoimmune hepatitis. 5. Treatment with another investigational drug or other experimental intervention within the last 30 days.

Inclusion Criteria

Exclusion Criteria

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Age 18 years or older
4. Presumed diagnosis of GBM deemed to be potentially resectable and deemed to be a good candidate for postoperative standard of care temozolomide and radiation therapy.
1. The surgical objective is for gross total resection (GTR)/near-total resection (NTR) defined as greater than or equal to 95% of contrast enhancing (CE) tumor removed plus less than or equal to 1 cm3 residual CE tumor. Patients with subtotal resection will still be eligible if at least 70% of the CE tumor is resected.
2. Eligibility will be confirmed after surgery when diagnosis of GBM IDH-wt confirmed prior to randomization.
3. Patients with prior biopsy or subtotal resection are eligible if no other anti-cancer treatment received for glioblastoma and additional resection indicated.
5. Ability to receive filgrastim (e.g. Neupogen), leukapheresis and 3 bi-weekly injections of DOC1021 near deep cervical lymph nodes + weekly pIFN x 6 weeks.
6. Females of reproductive potential must have a negative serum pregnancy test and agree to use effective contraception (as determined appropriate for the patient by the investigator) during study treatment.
7. Adequate kidney, liver, bone marrow function, and immune function, as follows:
1. Hemoglobin ≥ 8.0 gm/dL (use of transfusion or other intervention to achieve is acceptable)
2. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
3. Platelet count ≥ 75,000/mm3
4. Calculated creatinine clearance (CrCl) \> 30 mL/min using Cockcroft and Gault formula:
8. Karnofsky Performance Score ≥ 70

1. Multifocal, deep midline, infratentorial, recurrent, leptomeningeal or extracranial disease.
2. Patients who are pregnant or breastfeeding.
3. Known active HIV or hepatitis infection. Patients with HIV that is well-controlled and have undetectable viral titers remain eligible. Patients with history of HCV adequately treated such that RNA viral load is negative also remain eligible.
4. Any severe or uncontrolled medical condition or other condition that could affect participation in this study as determined by the investigator, including but not limited to uncontrolled or severe cardiac disease, systemic autoimmune disorders requiring immunosuppression in the past 2 years, autoimmune hyper/hypothyroidism, untreated vi-ral hepatitis, autoimmune hepatitis.
5. Treatment with another investigational drug or other experimental intervention within the last 30 days.

Contacts and Locations

Study Locations (Sites)

City of Hope

Duarte, California, 91010

United States

Collaborators and Investigators

Sponsor: Diakonos Oncology Corporation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-17

Study Completion Date2032-03

Study Record Updates

Study Start Date2025-03-17

Study Completion Date2032-03

Terms related to this study

Keywords Provided by Researchers

Dendritic Cell Vaccine
Immunotherapy
Tumor vaccine

Additional Relevant MeSH Terms

Glioblastoma (GBM)